Biologic Therapy
Cross-source consensus on Biologic Therapy from 2 sources and 0 claims.
2 sources · 0 claims
Risks & contraindications
Comparisons
Background
Evidence quality
Highlighted claims
- In the omalizumab and benralizumab subgroup of 67 patients, 2 patients had prior HES-related biologic therapy in the preceding 12 months. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- All biologic treatments suppress the immune pathways driving psoriasis without addressing root causes, and patients typically relapse upon discontinuation. — Psoriasis as a Gut-Driven Systemic Disease: Root Causes, Immune Pathways, and Naturopathic Treatment
- Adalimumab carries a well-documented paradoxical risk of inducing de novo psoriasis when administered for Crohn's disease. — Psoriasis as a Gut-Driven Systemic Disease: Root Causes, Immune Pathways, and Naturopathic Treatment
- Correcting the percentage of prior biologic therapy use ensures proper characterization of the trial population's treatment history. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- Apremilast's primary significance over injectable biologics is its oral administration route, which substantially improves patient acceptance. — Psoriasis as a Gut-Driven Systemic Disease: Root Causes, Immune Pathways, and Naturopathic Treatment